Several studies have previously reported significant upregulation of ATAD2 expression in solid tumors of distinct origins as well as its association with poor patients' outcome, especially in lung, breast, liver, ovarian and cervix cancers.43 This evidence concerns the gene ATAD2 and cervical cancer.